Drugs for Pulmonary Hypertension, Primary, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 317)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Furosemide |
Approved, Vet_approved |
Phase 4 |
|
54-31-9 |
3440 |
Synonyms:
2-furfurylamino-4-chloro-5-Sulfamoylbenzoate
2-furfurylamino-4-chloro-5-Sulfamoylbenzoic acid
2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid
2-furfurylamino-4-chloro-5-Sulphamoylbenzoate
2-furfurylamino-4-chloro-5-Sulphamoylbenzoic acid
41733-55-5 (mono-hydrochloride salt)
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
4-chloro-5-Sulfamoyl-N-furfuryl-anthranilate
4-chloro-5-Sulfamoyl-N-furfuryl-anthranilic acid
4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid
4-chloro-5-Sulphamoyl-N-furfuryl-anthranilate
4-chloro-5-Sulphamoyl-N-furfuryl-anthranilic acid
4-chloro-N-(2-Furylmethyl)-5-sulfamoylanthranilate
4-chloro-N-(2-Furylmethyl)-5-sulfamoylanthranilic acid
4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid
4-chloro-N-(2-Furylmethyl)-5-sulphamoylanthranilate
4-chloro-N-(2-Furylmethyl)-5-sulphamoylanthranilic acid
4-chloro-N-Furfuryl-5-sulfamoylanthranilate
4-chloro-N-Furfuryl-5-sulfamoylanthranilic acid
4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid
4-chloro-N-Furfuryl-5-sulphamoylanthranilate
4-chloro-N-Furfuryl-5-sulphamoylanthranilic acid
5-18-09-00555 (Beilstein Handbook Reference)
54-31-9
AB00052001
AC-11067
AC1L1FXW
AC1Q557O
Acetic acid potassium salt
Aisemide
AKOS000266625
Aldalix
Aldic
Aluzine
Anfuramaide
apo-Frusemide
Apo-Frusemide
apo-Furosemide
Apo-Furosemide
Aquarid
Aquasin
Arasemide
ARONIS24304
Beronald
BIDD:GT0139
Bio-0044
Bioretic
BPBio1_000443
BRD-K78010432-001-05-8
Bristab
Bristurin
BRN 0840915
BSPBio_000401
BSPBio_002054
C12H11ClN2O5S
CAS-54-31-9
CCRIS 1951
Cetasix
CHEBI:47426
CHEMBL35
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure
Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]
CID3440
CPD000058202
D00331
D005665
DB00695
DB07799
Depix
Desal
Desdemin
Di-Ademil
Dihydroflumethiazide
Dirine
Disal
Discoid
Disemide
Diucardin
Diumide-K
Diural
Diurapid
Diuretic salt
Diuretic Salt
Diurin
Diurolasa
Diusemide
Diusil
Diuzol
DivK1c_000575
Dranex
Dryptal
Durafurid
Edemid
Edenol
EINECS 200-203-6
Eliur
Elodrine
Endural
Errolon
Eutensin
F0182
F4381_SIGMA
Farsix
Finuret
Fluidrol
Fluss
Franyl
Frumex
Frumide
Frumil
Frusedan
Frusema
Frusemid
Frusemide
Frusemin
Frusenex
Frusetic
Frusid
Fu sid
Fulsix
Fuluvamide
Fuluvamine
fulvamide
FUN
Furanthril
Furanthryl
Furantral
Furantril
Furanturil
Furesis
Furetic
Furex
Furfan
Furix
Furmid
furo-Basan
Furo-Basan
Furobeta
Furocot
Furodiurol
Furodrix
Furomen
Furomex
Furomide M.D
Furomide m.d.
Furomide M.D.
furo-Puren
Furo-puren
Furo-Puren
Furorese
Furosan
Furose
Furosedon
Furosemid
Furosemida
Furosemida [INN-Spanish]
furosemide
Furosemide
Furosemide "mita"
Furosemide (JP15/USP/INN)
Furosemide [USAN:INN:JAN]
furosemide ''mita''
Furosemide monohydrochloride
Furosemide Monohydrochloride
Furosemide monosodium salt
Furosemide Monosodium Salt
FUROSEMIDE USP
Furosemidu
Furosemidu [Polish]
Furosemidum
Furosemidum [INN-Latin]
Furosemix
Furoside
|
Furosifar
Furosix
Furoter
Furovite
Fursemid
Fursemida
Fursemide
Fursol
Fusid
Fusidic acid
Golan
Hissuflux
HMS1569E03
HMS1920B03
HMS2090K06
HMS2091H05
HMS501M17
Hoe-058A
HSDB 3086
Hydol
Hydrenox
Hydrex
Hydro
Hydroled
hydro-Rapid
Hydro-rapid
Hydro-Rapid
I04-0179
IDI1_000575
Impugan
Jenafusid
Katlex
KBio1_000575
KBio2_001580
KBio2_004148
KBio2_006716
KBio3_001274
KBioGR_001259
KBioSS_001580
Kofuzon
Kolkin
Kutrix
Lasemid
Lasex
Lasiletten
Lasilix
Lasix
Lasix (TN)
Lasix retard
Lasix Retard
Lasix Special
Lasix, Frusemide, Furosemide
Laxur
Lazix
LB 502
LB-502
Leodrine
less Diur
Less diur
Less Diur
Liside
Logirene
Lowpston
Lowpstron
LS-204
Luscek
Macasirool
Marsemide
Metflorylthiazidine
Methforylthiazidine
Mirfat
Mita
MLS001066374
MLS001306403
Moilarorin
MolPort-001-641-065
Myrosemide
Nadis
NCGC00016241-01
NCGC00090893-01
NCGC00090893-02
NCGC00090893-03
NCGC00090893-05
NCGC00090893-06
NCI-C55936
Nelsix
neo-Renal
Neo-renal
Neo-Renal
Nephron
Nicorol
NINDS_000575
Novosemide
NSC 269420
NSC269420
Octan draselny
Octan Draselny
Odemase
Odemex
Oedemex
Olmagran
Oprea1_667724
Osyrol
Polysquall a
Polysquall A
Prefemin
Prestwick_752
Prestwick0_000341
Prestwick1_000341
Prestwick2_000341
Prestwick3_000341
Profemin
Promedes
Promide
Protargen
Puresis
Radisemide
Radonna
Radouna
Retep
Rodiuran
Rontyl
Rosemide
Rosis
Rusyde
S1603_Selleck
Sal diureticum
Sal Diureticum
Salinex
Salix
Salix (brand of furosemide)
Salix (brand OF furosemide)
Salurex
Salurid
Saluron
SAM002264614
Seguril
Selectofur
Sigasalur
Sisuril
SMP1_000129
SMR000058202
SPBio_001129
SPBio_002322
Spectrum_001100
SPECTRUM1500310
Spectrum2_001005
Spectrum3_000437
Spectrum4_000560
Spectrum5_000744
Spirofur
STK177334
Synephron
TL8003563
Transit
Trofurit
UNII-7LXU5N7ZO5
UPCMLD-DP022
UPCMLD-DP022:001
Uremide
Uresix
Urex
Urex-m
Urex-M
Urian
Uridon
Uritol
Urosemide
Vergonil
Vesix
WLN: T5OJ B1MR CG FVQ DSZW
Yidoli
Zafimida
|
|
2 |
|
Tadalafil |
Approved, Investigational |
Phase 4 |
|
171596-29-5 |
110635 |
Synonyms:
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
351, IC
6-benzo[1,3]DIOXOL-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
Acdirca
Adcirca
ADCIRCA
C429886
CHEBI:41488
CHEMBL779
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
CID110635
CPD000466321
D02008
DB00820
FT-0080116
GF 196960
GF-196960
HMS2051N17
|
HSDB 7303
IC 351
Ic351
IC-351
ICOS 351
KS-1117
Lilly brand of tadalafil
LS-186558
LS-187015
LS-187770
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadalafilo
Tadanafil
UNII-742SXX0ICT
ZINC03993855
|
|
3 |
|
Silver sulfadiazine |
Approved, Vet_approved |
Phase 4 |
|
22199-08-2 |
441244 |
Synonyms:
(4-Amino-N-pyrimidin-2-ylbenzenesulphonamidato-NN,O1)silver
22199-08-2
481181_ALDRICH
4-Amino-N-(2-pyrimidinyl)benzenesulfonamide silver salt
4-amino-N-pyrimidin-2-ylbenzenesulfonamide
Abbott Brand of Silver Sulfadiazine
AC-19319
AC1L1KQS
AC1L9ATF
AC1L9Q6O
AC1NUR63
AC1O8LAG
AC-3535
AKOS005111099
AKOS005111434
Aldo Brand of Silver Sulfadiazine
ARONIS23842
Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, monosilver(1+) salt
Benzenesulfonamide,4-amino-N-2-pyrimidinyl-, silver complex
Brandiazin
C10H9N4O2S.Ag
CHEBI:9142
CHEMBL1200766
CID11947738
CID31011
CID441244
CID452254
CID5459124
D00433
D012837
DB05245
Dermazin
Dermazine
EINECS 244-834-5
Flamazine
Flammazine
Geben
I06-0145
I06-145
LS-147839
Major Brand of Silver Sulfadiazine
medphano Brand of Silver Sulfadiazine
MLS000069662
MolPort-003-934-423
MolPort-003-986-619
MolPort-006-395-987
Monarch Brand of Silver Sulfadiazine
N(sup 1)-2-Pyrimidinylsulfanilamide monosilver(1+) salt
N1-2-Pyrimidinylsulfanilamide monosilver(1+) salt
NSC 625324
NSC625324
|
Par Brand 1 of Silver Sulfadiazine
Par Brand 2 of Silver Sulfadiazine
Par Brand 3 of Silver Sulfadiazine
Pharmascience Brand of Silver Sulfadiazine
Rhone Poulenc Rorer Brand of Silver Sulfadiazine
Rhone-Poulenc Rorer Brand of Silver Sulfadiazine
S0595
Sherwood Brand of Silver Sulfadiazine
Sicazine
Silbertone
Sildaflo
Silvadene
Silvadene (TN)
Silvederma
silver
silver (4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide
silver 4-amino-N-pyrimidin-2-ylbenzenesulfonamide
silver sulfadiazinate
Silver sulfadiazinate
silver sulfadiazine
Silver sulfadiazine
Silver Sulfafdiazine
Silver sulphadiazine
silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide
Silver(I) sulfadiazine
Smith & Nephew Brand of Silver Sulfadiazine
SMR000059233
Solvay Brand of Silver Sulfadiazine
SSD
SSD (1% Silver Sulfadiazine Cream USP)
SSD AF
STL069502
Sulfadiazin silber
Sulfadiazin, silbersalz
Sulfadiazine silver
SULFADIAZINE SILVER
Sulfadiazine silver (JP15)
Sulfadiazine silver salt
Sulfadiazine silverSilvadene
Sulfadiazine, silver
Sulfadiazine, silver (USP)
Sulfadiazine, Silver [USAN]
Sulfafdiazine, Silver
Sulfanilamide, N(sup 1)-2-pyrimidinyl-, monosilver(1+) salt
Sulfanilamide,N1-2-pyrimidinyl-, monosilver(1+) salt
Sulfargen
Thermazene
TL8001845
UNII-W46JY43EJR
Zenith Brand of Silver Sulfadiazine
|
|
4 |
|
Clevidipine |
Approved, Investigational |
Phase 4 |
|
167221-71-8 |
|
Synonyms:
Clevidipine
Clevidipine butyrate
|
|
|
5 |
|
Riociguat |
Approved |
Phase 4 |
|
625115-55-1 |
|
Synonyms:
Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate
Riociguat
|
|
|
6 |
|
Angiotensin II |
Approved, Investigational |
Phase 4 |
|
4474-91-3, 11128-99-7, 68521-88-0 |
172198 |
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
5 L Isoleucine angiotensin II
5-isoleucine-angiotensin II
5-Isoleucine-angiotensin II
5-L-Isoleucine angiotensin II
5-L-isoleucineangiotensin II
5-L-Isoleucineangiotensin II
Ang II
ANG-(1-8)octapeptide
Angiotensin
Angiotensin 2
Angiotensin II
Angiotensin II (human)
Angiotensin II (mouse)
Angiotensin II, 5-L-isoleucine
|
Angiotensin-(1-8) octapeptide
Angiotonin
Asp-arg-val-tyr-ile-his-pro-phe
Human angiotensin II
Hypertensin
II, 5-L-isoleucine angiotensin
Ile(5)-angiotensin II
Ile5-angiotensin II
Isoleucine(5)-angiotensin
Isoleucine(5)-angiotensin II
isoleucine5-angiotensin II
Isoleucyl(5)-angiotensin II
N-(1-(N-(N-(N-(N-(N(2)-L-a-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-alpha-Aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
N-(1-(N-(N-(N-(N-(N(2)-L-α-aspartyl-L-arginyl)-L-valyl)-L-tyrosyl)-L-isoleucyl)-L-histidyl)-L-prolyl)-L-phenylalanine
Valyl(5)-angiotensin II
|
|
7 |
|
Valsartan |
Approved, Investigational |
Phase 4 |
|
137862-53-4 |
60846 |
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
|Tareg
137862-53-4
AC1L1U1M
AC1Q5QIK
AC-4543
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
Bio-0796
BRD-K45158365-001-02-3
BSPBio_003501
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
Kalpress
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
Lacer brand of valsartan
|
LS-161334
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
Miten
MLS000759423
MLS001424088
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
Nisis
Nisis||
Novartis brand of valsartan
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Provas
S1894_Selleck
SAM001246581
Sanol brand of valsartan
Schwarz brand of valsartan
SMR000466318
SPBio_001260
Spectrum_001796
SPECTRUM1505209
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Tareg
TL8000869
UNII-80M03YXJ7I
Vals
Valsarran
valsartan
Valsartan
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
walsartan
|
|
8 |
|
Spironolactone |
Approved |
Phase 4 |
|
52-01-7, 1952-01-7 |
5833 |
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
496916-40-6
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
52-01-7
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
AB00513806
Abbolactone
AC1L1L8Q
AC-4214
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone a
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm brand OF spironolactone
Alphapharm Brand of Spironolactone
Alpharma brand OF spironolactone
Alpharma Brand of Spironolactone
Alter brand OF spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne brand OF spironolactone
Ashbourne Brand of Spironolactone
Azupharma brand OF spironolactone
Azupharma Brand of Spironolactone
betapharm Brand of Spironolactone
Betapharm brand OF spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
Cardel brand OF spironolactone
Cardel Brand of Spironolactone
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
ct Arzneimittel Brand of Spironolactone
CT Arzneimittel brand OF spironolactone
ct-Arzneimittel Brand of Spironolactone
CT-Arzneimittel brand OF spironolactone
D00443
D013148
DB00421
Deverol
dexo Brand OF spironolactone
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona [INN-Spanish]
Espironolactona alter
Espironolactona Alter
Espironolactona mundogen
Espironolactona Mundogen
Euteberol
Flumach
Frumikal
Generosan brand OF spironolactone
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
Hormosan brand OF spironolactone
Hormosan Brand of Spironolactone
HSDB 3184
I06-1970
Jenapharm brand OF spironolactone
Jenapharm Brand of Spironolactone
Jenaspiron
Lacalmin
Lacdene
Laractone
LS-118614
LT00772287
Mayoly-spindler brand OF spironolactone
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura brand OF spironolactone
Merck dura Brand of Spironolactone
MLS001074672
MLS001333253
MLS001333254
|
MLS002153245
MLS002207058
Mundogen brand OF spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
NCGC00164397-02
Nefurofan
novo Spiroton
Novo Spiroton
Novopharm brand OF spironolactone
Novopharm Brand of Spironolactone
novo-Spiroton
NovoSpiroton
Novo-Spiroton
NSC 150399
NSC150399
Osyrol
Pfizer brand OF spironolactone
Pfizer Brand of Spironolactone
Pharmafrid brand OF spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche brand OF spironolactone
Roche Brand of Spironolactone
S0260
S3378_SIGMA
Sagisal
SAM002264648
SC 9420
SC9420
SC-9420
Searle brand OF spironolactone
Searle Brand of Spironolactone
Sincomen
SMR000471892
SNL
SPBio_002115
Spiractin
Spiresis
Spiretic
Spiridon
spiro L.U.T.
Spiro L.U.T.
spiro von ct
spiro Von CT
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
spirono Isis
Spirono Isis
Spironocompren
spirono-Isis
Spirono-Isis
spironolactone
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactone A
Spironolactonum
Spironolactonum [INN-Latin]
spironolattone
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Spiro-Tablinen
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
von ct, spiro
Von CT, spiro
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Wörwag brand OF spironolactone
Xenalon
ZINC03861599
|
|
9 |
|
Epoprostenol |
Approved |
Phase 4 |
|
35121-78-9, 61849-14-7 |
5282411 5280427 |
Synonyms:
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-alpha-Epoxy-11-alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9α-epoxy-11α,15-dihydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-6,9α-epoxy-11α,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoate
(5Z,13E,15S)-6,9a-Epoxy-11a,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oate
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z,9α,11α,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-Oic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
136626-78-3
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
5-[5-hydroxy-4-(3-hydroxyoct-1-enyl)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
61849-14-7
63748-50-5
63859-31-4
AC1L18LX
AC1L3FZB
AC1NQX0K
AC1NR00P
AC1O51WG
AC1O5HI7
AR-1I7150
BIDD:GT0514
Bio2_000216
Bio2_000696
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
C01312
CHEBI:15552
CHEMBL1139
CHEMBL307845
CID114805
CID11969614
CID159
CID5280427
CID5282411
|
CID6434194
CID6450541
CID9864371
CID9975312
D00106
DB01240
Epoprostanol
epoprostenol
Epoprostenol
Epoprostenol (TN)
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenol sodium
Epoprostenol sodium salt, (5Z,9alpha,11alpha,13E,15S)-isomer
Epoprostenolum
Epoprostenolum [INN-Latin]
Flolan
HMS1791K18
HMS1989K18
IDI1_033966
KBio2_000216
KBio2_002784
KBio2_005352
KBio3_000431
KBio3_000432
KBioGR_000216
KBioSS_000216
KB-IV-24
LMFA03010087
LS-125828
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PDSP1_001721
PDSP2_001704
PGI(sub 2)
PGI2
PG-I2
PGX
prostacyclin
Prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin I
Prostaglandin I(2)
prostaglandin I2
Prostaglandin I2
Prostaglandin X
Prostaglandins X
SMP2_000227
TRY 200
Try-200
U 53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
|
|
10 |
|
Macitentan |
Approved |
Phase 4 |
|
441798-33-0 |
|
Synonyms:
|
11 |
|
Lidocaine |
Approved, Vet_approved |
Phase 4 |
|
137-58-6 |
3676 |
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(diethylamino)-2',6'-Acetoxylidide
2-(Diethylamino)-2',6'-acetoxylidide
2-(diethylamino)-N-(2,6-Dimethylphenyl)acetamide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-2ETN-2MePhAcN
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
a-diethylamino-2,6-Dimethylacetanilide
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
AKOS001026768
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
Alphacaine
alpha-diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-Dimethylacetanilide
alpha-Diethylamino-2,6-dimethylacetanilide
Anestacon
Anestacon Jelly
ARONIS23855
Astrazeneca brand OF lidocaine
BIDD:GT0342
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
C07073
C14H22N2O
Cappicaine
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
Cito optadren
CPD000058189
Cuivasil
D00358
Dalcaine
DB00281
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jenapharm brand OF lidocanine hydrochloride
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L0156
L1026_SIGMA
L7757_SIGMA
Lanabiotic
L-Caine
Leostesin
|
Lida-Mantle
Lidocaina
Lidocaína
Lidocaina [INN-Spanish]
lidocaine
Lidocaine
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine [USAN:INN:JAN]
Lidocaine carbonate
Lidocaine Carbonate
Lidocaine carbonate (2:1)
Lidocaine hydrocarbonate
Lidocaine Hydrocarbonate
Lidocaine hydrochloride
Lidocaine monoacetate
Lidocaine monohydrochloride
Lidocaine Monohydrochloride
Lidocaine monohydrochloride, monohydrate
Lidocaine sulfate (1:1)
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
LIDOPEN
Lignocaine
Lignocainum
Lingocaine
Lopac0_000669
Lopac-L-5647
LQZ
LS-805
Maricaine
Maybridge1_002571
MLS000069724
MLS000758263
MLS001074177
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
nchembio.65-comp16
NINDS_000174
Norwood Sunburn Spray
Novocol brand OF lidocaine hydrochloride
NSC 40030
NSC40030
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
Solarcaine aloe extra burn relief cream
Solcain
SPBio_001525
SPBio_002100
Spectrum_001118
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
STK552033
Strathmann brand OF lidocaine hydrochloride
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
α-diethylamino-2,6-dimethylacetanilide
|
|
12 |
|
Beraprost |
Investigational |
Phase 4 |
|
88430-50-6 |
|
13 |
|
Tezosentan |
Investigational |
Phase 4 |
|
180384-57-0 |
|
14 |
|
Vardenafil Dihydrochloride |
|
Phase 4 |
|
|
|
15 |
|
Sodium Potassium Chloride Symporter Inhibitors |
|
Phase 4 |
|
|
|
16 |
|
Angiotensin II Type 1 Receptor Blockers |
|
Phase 4 |
|
|
|
17 |
|
Angiotensinogen |
|
Phase 4 |
|
|
|
18 |
|
Angiotensin Receptor Antagonists |
|
Phase 4 |
|
|
|
19 |
|
LCZ 696 |
|
Phase 4 |
|
|
|
20 |
|
Giapreza |
|
Phase 4 |
|
|
|
21 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
22 |
|
Mineralocorticoids |
|
Phase 4 |
|
|
|
23 |
|
Mineralocorticoid Receptor Antagonists |
|
Phase 4 |
|
|
|
24 |
|
diuretics |
|
Phase 4 |
|
|
|
25 |
|
Endothelin A Receptor Antagonists |
|
Phase 4 |
|
|
|
26 |
|
Chelating Agents |
|
Phase 4 |
|
|
|
27 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
28 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
29 |
|
Anti-Arrhythmia Agents |
|
Phase 4 |
|
|
|
30 |
|
Natriuretic Peptide, Brain |
|
Phase 4 |
|
|
|
31 |
|
Diuretics, Potassium Sparing |
|
Phase 4 |
|
|
|
32 |
|
Sodium Channel Blockers |
|
Phase 4 |
|
|
|
33 |
|
Anesthetics |
|
Phase 4 |
|
|
|
34 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
35 |
|
Udenafil |
Approved, Investigational |
Phase 2, Phase 3 |
|
268203-93-6 |
6918523 |
Synonyms:
3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
5-(2-Propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one
AC1OCFJA
CID6918523
DA 8159
DA-8159
|
DA-8159udenafil
DB06267
I14-12963
Udenafil
Zidena
Zydena
|
|
36 |
|
Ranolazine |
Approved, Investigational |
Phase 3 |
|
142387-99-3, 95635-55-5 |
56959 |
Synonyms:
( -)-Ranolazine
(-)-Ranolazine
142387-99-3
95635-55-5
AC-1673
AC1L1M17
AC1Q5LYD
BRD-A97674275-001-01-9
BSPBio_002276
CHEMBL1404
CID56959
CVT-303
D05700
DB00243
Dihydrochloride, ranolazine
HCL, Ranolazine
HMS1922F16
HMS2090L09
HMS2093D21
Hydrochloride, ranolazine
I01-2008
I06-0160
KEG-1295
Latixa
Lopac0_001062
LS-187267
MLS002154149
MolPort-003-666-653
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
|
N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
NCGC00015897-05
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
RAN D
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
Ranolazina
ranolazine
Ranolazine
RANOLAZINE
Ranolazine (USAN/INN)
Ranolazine 2HCl
Ranolazine 2HCL
Ranolazine dihydrochloride
Ranolazine Dihydrochloride
Ranolazine HCL
Ranolazine hydrochloride
Renolazine
RS-43285
RS-43285-003
S1799_Selleck
SMR000857382
SPECTRUM1505366
UNII-A6IEZ5M406
|
|
37 |
|
Trimetazidine |
Approved, Investigational |
Phase 2, Phase 3 |
|
5011-34-7 |
|
Synonyms:
1-[2,3,4-trimethoxybenzyl] piperazine dihydrochloride
|
|
|
38 |
|
Iodine |
Approved, Investigational |
Phase 3 |
|
7553-56-2 |
807 |
Synonyms:
diiodine
I2
Iode
Iodine-molecule
Iodio
iodo
|
Iodum
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
39 |
|
Mannitol |
Approved, Investigational |
Phase 3 |
|
69-65-8 |
6251 453 |
Synonyms:
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
Ambap69-65-8
AR-1J3861
bmse000099
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
cpd without stereochemical designation
D-(-)-Mannitol
D00062
D008353
Diosmol
DL-Mannitol
D-mannite
D-mannitol
D-Mannitol
D-Mannitol (JP15)
Dulcite
e 421
e421
e-421
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Hexahydroxyhexane
Hexanhexol
HSDB 714
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
|
M9546_SIAL
M9647_SIAL
Manicol
manita
Manitol
Maniton S
Maniton-S
Manna sugar
Manna Sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit P
Mannite
mannitol
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol [USAN]
Mannitol 10%
Mannitol 10% In Plastic Container
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Mannitol 15%
Mannitol 15% In Plastic Container
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
Mannitol 20%
Mannitol 20% In Plastic Container
MANNITOL 25%
Mannitol 5%
Mannitol 5% In Plastic Container
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
Mannitolum
Mannogem 2080
Marine crystal
Marine Crystal
MLS001335977
MLS001335978
MolPort-003-927-039
MTL
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Osmitrol 15% In Water
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Osmitrol 20% In Water
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Osmitrol 5% In Water
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM no. 35
SDM No. 35
SMR000857324
Sorbitol-Mannitol
SORBITOL-MANNITOL IN PLASTIC CONTAINER
TL806434
UNII-3OWL53L36A
ZINC02041302
|
|
40 |
|
tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
41 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
42 |
|
Ambrisentan |
Approved, Investigational |
Phase 2, Phase 3 |
|
177036-94-1 |
6918493 |
Synonyms:
(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid
(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy- 3,3-diphenylpropanoic acid
177036-94-1
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid
2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
AC1L53VT
Ambrisentan
Ambrisentan [INN]
Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe
BSF 208075
BSF208075
BSF-208075
C467894
CHEBI:205299
CHEMBL302753
|
CID197712
Gilead brand of ambrisentan
I06-2077
Letairis
LS-186563
LS-187364
LU 208075
LU208075
LU-208075
MLS001195278
MolPort-002-945-567
NCGC00160662-01
SMR000502713
ST51051295
STK097095
UNII-HW6NV07QEC
|
|
43 |
|
Selexipag |
Approved |
Phase 3 |
|
475086-01-2 |
|
Synonyms:
|
44 |
|
Nitric Oxide |
Approved |
Phase 3 |
|
10102-43-9 |
145068 |
Synonyms:
(.)NO
(no)(.)
(NO)(.)
[no]
[NO]
10102-43-9
14332-28-6
295566_ALDRICH
51005-20-0
51005-21-1
53851-19-7
90452-29-2
AC1L1ADQ
AC1L3QHF
AC1Q6QZ0
AR-1K7463
Bioxyde d'azote
Bioxyde d'azote [French]
C00533
CCRIS 4319
CHEMBL1200689
CHEMBL1234765
CID145068
CID945
D00074
D009569
DB00435
EDRF
EINECS 233-271-0
Endogenous nitrate vasodilator
Endogenous Nitrate Vasodilator
Endothelium-derived nitric oxide
Endothelium-Derived Nitric Oxide
endothelium-derived relaxing factor
Endothelium-derived relaxing factor
HNO
HSDB 1246
INOmax
INOmax (TN)
LS-192158
LS-7547
MolPort-003-929-452
Mononitrogen monoxide
Monoxide, mononitrogen
Monoxide, Mononitrogen
Monoxide, nitrogen
Monoxide, Nitrogen
monoxido de nitrogeno
monoxido De nitrogeno
Monóxido de nitrógeno
monoxyde d'azote
Monoxyde d'azote
Nitrate vasodilator, endogenous
Nitrate Vasodilator, Endogenous
|
nitric oxide
Nitric oxide
Nitric oxide (JAN)
Nitric oxide 10% by volume or more
Nitric oxide trimer
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, compressed [UN1660] [Poison gas]
Nitric oxide, endothelium derived
Nitric Oxide, Endothelium Derived
Nitric oxide, endothelium-derived
Nitric Oxide, Endothelium-Derived
NITRIC-OXIDE
nitrogen monooxide
Nitrogen monooxide
nitrogen monoxide
Nitrogen monoxide
Nitrogen oxide
Nitrogen oxide (NO)
Nitrogen protoxide
nitrosyl
Nitrosyl
Nitrosyl hydride
Nitrosyl hydride ((NO)H)
Nitrosyl radical
Nitroxide radical
Nitroxyl
NO
no(.)
NO(.)
OHM 11771
Oxide, nitric
Oxide, Nitric
oxido de nitrogeno(II)
oxido De nitrogeno(II)
óxido de nitrógeno(II)
oxido nitrico
oxido Nitrico
óxido nítrico
oxidonitrogen(.)
oxoazanyl
oxyde azotique
Oxyde azotique
Oxyde nitrique
Oxyde nitrique [French]
RCRA waste no. P076
Stickmonoxyd
Stickmonoxyd [German]
Stickstoff(II)-oxid
Stickstoffmonoxid
UN 1660
UN1660
UNII-31C4KY9ESH
Vasodilator, endogenous nitrate
Vasodilator, Endogenous Nitrate
|
|
45 |
|
Lipid Regulating Agents |
|
Phase 3 |
|
|
|
46 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
47 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
48 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
49 |
|
Rosuvastatin Calcium |
|
Phase 3 |
|
147098-20-2 |
|
50 |
|
Hypoglycemic Agents |
|
Phase 2, Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 699)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension |
Unknown status |
NCT01288651 |
Phase 4 |
Ferricarboxymaltose |
2 |
Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial |
Unknown status |
NCT03236818 |
Phase 4 |
ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan) |
3 |
Hemodynamic Evaluation of Patients With Pulmonary Arterial Hypertension. Response to Sildenafil Treatment |
Unknown status |
NCT00483626 |
Phase 4 |
oral sildenafil |
4 |
Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease |
Unknown status |
NCT01116063 |
Phase 4 |
Inhaled iloprost |
5 |
Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis |
Unknown status |
NCT03053739 |
Phase 4 |
Sildenafil 20mg and Bosentan 62.5mg;Sildenafil 20mg and Placebo |
6 |
Effects of Spironolactone on Collagen Metabolism in Pulmonary Arterial Hypertension |
Unknown status |
NCT01468571 |
Phase 4 |
Spironolactone;Placebo |
7 |
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients |
Unknown status |
NCT01382368 |
Phase 4 |
Sildenafil |
8 |
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost |
Unknown status |
NCT01649739 |
Phase 4 |
Levitra |
9 |
Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive |
Unknown status |
NCT02531581 |
Phase 4 |
Furosemide;NaCl 9% isotonic |
10 |
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids. |
Unknown status |
NCT00705588 |
Phase 4 |
Tadalafil;Vardenafil |
11 |
Effect of Endothelin Receptor Blocker Tracleer on Toruniquet-associated Hypertension During Total Knee Arthroplasty |
Unknown status |
NCT03229694 |
Phase 4 |
Tracleer 125Mg Tablet;Placebo |
12 |
An Open-label Extension of Study AC-066A401 Investigating the Safety and Tolerability of ACT-385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01105117 |
Phase 4 |
ACT-385781A (Actelion Epoprostenol);Flolan® |
13 |
TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT03055221 |
Phase 4 |
Intravenous Treprostinil |
14 |
A Phase IV, Open-label, Randomized, Multicenter Study of the Safety, Tolerability,and Pharmacokinetics of ACT- 385781A Compared to Flolan® in Injectable Prostanoid Treatment-naïve Patients With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT01105091 |
Phase 4 |
ACT-385781A (Actelion Epoprostenol);Flolan® |
15 |
Open Label, Non Comparative Study to Investigate the Effect of Bosentan on Pulmonary Artery Remodelling in Pulmonary Arterial Hypertension (PAH). |
Completed |
NCT00595049 |
Phase 4 |
bosentan |
16 |
An Open Label, Multi-center Study Evaluating the Safety of Long-term Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis® (Iloprost) in Subjects With Pulmonary Arterial Hypertension. |
Completed |
NCT00741819 |
Phase 4 |
Inhaled treprostinil |
17 |
A Multinational, Multicentre, Randomized, Double-blind Study To Assess The Efficacy And Safety Of Oral Sildenafil 20mg Tid Or Placebo When Added To Bosentan In The Treatment Of Subjects, Aged 18 Years And Above, With Pulmonary Arterial Hypertension (Pah) |
Completed |
NCT00323297 |
Phase 4 |
Bosentan;Bosentan;Sildenafil Citrate |
18 |
An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Patients With Exercise Induced Pulmonary Arterial Hypertension |
Completed |
NCT01338636 |
Phase 4 |
Ambrisentan |
19 |
A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal |
Completed |
NCT02891850 |
Phase 4 |
Adempas (Riociguat, BAY63-2521);Sildenafil;Tadalafil |
20 |
A 16 Week, Open Label, Multi-centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT02847260 |
Phase 4 |
Remodulin |
21 |
COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling |
Completed |
NCT00433329 |
Phase 4 |
Bosentan;Sildenafil |
22 |
A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension |
Completed |
NCT01642407 |
Phase 4 |
Sildenafil |
23 |
A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts |
Completed |
NCT03078907 |
Phase 4 |
Selexipag;Placebo |
24 |
TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension |
Completed |
NCT00082186 |
Phase 4 |
bosentan |
25 |
An Open-label, Multicenter Study of Ambrisentan and a Phosphodiesterase Type-5 Inhibitor Combination Therapy in Subjects With Pulmonary Arterial Hypertension Who Have Demonstrated a Sub-Optimal Response to a Phosphodiesterase Type-5 Inhibitor |
Completed |
NCT00617305 |
Phase 4 |
Ambrisentan;Placebo;Sildenafil;Tadalafil |
26 |
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00317486 |
Phase 4 |
bosentan |
27 |
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis |
Completed |
NCT01042158 |
Phase 4 |
tadalafil and ambrisentan upfront combination therapy |
28 |
A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging |
Completed |
NCT02310672 |
Phase 4 |
Macitentan |
29 |
Effects of Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Morbidity and Mortality in Symptomatic Patients With Pulmonary Arterial Hypertension - A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Prospective, Event Driven Phase IV Study |
Completed |
NCT00303459 |
Phase 4 |
bosentan;placebo |
30 |
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension |
Completed |
NCT01330108 |
Phase 4 |
ambrisentan |
31 |
Therapy of Pulmonary Arterial Hypertension (PAH) With Bosentan in Patients With Eisenmenger Syndrome |
Completed |
NCT00266162 |
Phase 4 |
Bosentan administration |
32 |
A Multi-Center, Open-Label Extension Study to Protocol AC-052-405 to Evaluate the Safety and Efficacy of Tracleer (Bosentan) in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology |
Completed |
NCT00367770 |
Phase 4 |
Tracleer® |
33 |
An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLANâ„¢ in Japanese Subjects With Pulmonary Arterial Hypertension (PAH) |
Completed |
NCT02705807 |
Phase 4 |
FLOLAN injection with currently marketed diluent;FLOLAN injection with reformulated diluent |
34 |
A Multicenter, Randomized, Parallel Placebo-Controlled Study of the Safety and Efficacy of Subcutaneous Remodulin® Therapy After Transition From Flolan® in Patients With Pulmonary Arterial Hypertension |
Completed |
NCT00058929 |
Phase 4 |
treprostinil sodium |
35 |
Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension |
Completed |
NCT00004754 |
Phase 4 |
epoprostenol |
36 |
A Single-arm, Open Label Study Evaluating the Impact on Lifestyle of a New Thermo Stable Formulation of FLOLAN® in Subjects With Pulmonary Arterial Hypertension (PAH). (FLOLAN® is a Registered Trademark of the GlaxoSmithKline Group of Companies.) |
Completed |
NCT01462565 |
Phase 4 |
current marketed FLOLAN (epoprostenol sodium);new thermo stable formulation of epoprostenol sodium |
37 |
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan: A Prospective Single Center, Open Label, Pilot Study |
Completed |
NCT01051960 |
Phase 4 |
Ambrisentan |
38 |
A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment |
Completed |
NCT02191137 |
Phase 4 |
Riociguat (Adempas, BAY63-2521) |
39 |
Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension |
Completed |
NCT00403650 |
Phase 4 |
Iloprost |
40 |
Rapid Switch From Intravenous Epoprostenol to Intravenous Remodulin® (Treprostinil Sodium) in Patients With Stable Pulmonary Arterial Hypertension: Safety, Efficacy and Treatment Satisfaction |
Completed |
NCT00373360 |
Phase 4 |
treprostinil sodium |
41 |
Transition From Parenteral Prostanoids to Inhaled Treprostinil |
Completed |
NCT01268553 |
Phase 4 |
Treprostinil |
42 |
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE) |
Completed |
NCT01121458 |
Phase 4 |
Clevidipine |
43 |
The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure |
Completed |
NCT02024386 |
Phase 4 |
Riociguat |
44 |
Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect |
Completed |
NCT03431649 |
Phase 4 |
Beraprost Sodium;Sildenafil Citrate |
45 |
Phase IV Study on the Effects of Sildenafil in Combination With Pulmonary Rehabilitation Program on Exercise Tolerance in Patients With COPD and Pulmonary Hypertension |
Completed |
NCT01055405 |
Phase 4 |
Sildenafil |
46 |
CombinatiON Up-FRON t Therapy for PAH - A Phase 4, Randomized, Multicenter Study of Inhaled Treprostinil in Treatment naïve Pulmonary Arterial Hypertension Patients Starting on Tadalafil |
Completed |
NCT01305252 |
Phase 4 |
treprostinil inhalations;tadalafil |
47 |
Acute Effects of a Single Dose of Sildenafil (20mg/40mg) on Pulmonary Haemodynamics and Gas Exchange at Rest and During Exercise in COPD Patients With Pulmonary Hypertension |
Completed |
NCT00491803 |
Phase 4 |
Sildenafil;Sildenafil |
48 |
Single Dose Sildenafil in Heart Failure Patients Improves 6-minute Walk Test by a Reduction in Left Ventricular Filling Pressure |
Completed |
NCT00781508 |
Phase 4 |
sildenafil |
49 |
Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A |
Completed |
NCT01803828 |
Phase 4 |
Tadalafil;Placebo |
50 |
A MULTINATIONAL, MULTICENTER STUDY TO ASSESS THE EFFECTS OF ORAL SILDENAFIL ON MORTALITY IN ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) |
Recruiting |
NCT02060487 |
Phase 4 |
sildenafil citrate;sildenafil citrate;sildenafil citrate |
|